A combination therapy involving dabrafenib and trametinib has demonstrated a clear therapeutic impact in children diagnosed with low- and high-grade gliomas carrying BRAF mutations.
Gliomas are malignant brain tumors originating in glial cells, the supportive cells of the brain. The BRAF gene produces the B-Raf protein, also known as v-Raf murine sarcoma viral oncogene homolog B.
Conducted as a Phase II trial, this research, led by UCL and Great Ormond Street Hospital, was published in the Journal of Clinical Oncology and the New England Journal of Medicine.
In the case of pediatric low-grade gliomas, the standard treatment involves complete surgical removal. However, when surgery is not feasible, additional interventions like chemotherapy become necessary. Such patients often face recurring episodes, disease advancement, and significant side effects.
The trial involved 73 kids with BRAF-mutated low-grade gliomas who received treatment with Dabrafenib and Trametinib. Their outcomes were compared to those of 37 patients treated with conventional chemotherapy drugs.
News in Same Category
Can Navitoclax be a Lower Back Pain Breakthrough?
Tobacco-Related Cancers Claim 1.3 Million Lives Yearly in India and Six Other Countries
Rising Type 2 Diabetes Cases in Children Linked to Changing Lifestyles
Israeli Military’s Attacks on Gaza Healthcare Spark Global Outcry
Tragic Measles Death in Malappuram Highlights Urgent Vaccination Need
Study Links Human Behavior to COVID-19 Evolution
Genetic Screening Offers Vital Treatment Insights for Familial Hypercholesterolemia
Soda Intake in Youth Linked to Future Alcohol Use and Cognitive Effects
Raw Meat Diet Increases Risk of Antibiotic-Resistant E. coli in Dogs
AIIMS Delhi Adds 63 Free Drugs for Low-Income Patients
